Targeting vascular endothelial growth factor in angina therapy

Bibliography

• AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics – 2005 Update. American Heart Association (2005).
   Google Scholar
• JONES EL, CRAVER JM, GUYTON RA et al.: Importance of complete revascularization in performance of the coronary bypass operation. Am. J. Cardiol. (1983) 51(1):7-12.
   PubMed Web of Science ®Google Scholar
• MCNEER JF, CONLEY MJ, STARMER CF et al.: Complete and incomplete revascularization at aortocoronary bypass surgery: experience with 392 consecutive patients. Am. Heart J. (1974) 88(2):176-182.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenic therapy of the human heart. Circulation (1998) 97(7):628-629.
   PubMed Web of Science ®Google Scholar
• SELLKE FW, LAHAM RJ, EDELMAN ER, PEARLMAN JD, SIMONS M: Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg. (1998) 65(6):1540-1544.
   PubMed Web of Science ®Google Scholar
• MOON MR, SUNDT TM, 3RD, PASQUE MK et al.: Influence of internal mammary artery grafting and completeness of revascularization on long-term outcome in octogenarians. Ann. Thorac. Surg. (2001) 72(6):2003-2007.
   PubMed Web of Science ®Google Scholar
• VANDER SALM TJ, KIP KE, JONES RH et al.: What constitutes optimal surgical revascularization? Answers from the Bypass Angioplasty Revascularization Investigation (BARI). J. Am. Coll. Cardiol. (2002) 39(4):565-572.
   PubMed Web of Science ®Google Scholar
• MCLELLAN CS, GHALI WA, LABINAZ M et al.: Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am. Heart J. (2005) 150(4):800-806.
   PubMed Web of Science ®Google Scholar
• KLEISLI T, CHENG W, JACOBS MJ et al.: In the current era, complete revascularization improves survival after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. (2005) 129(6):1283-1291.
   PubMed Web of Science ®Google Scholar
• ELLIS SG, CHEW D, CHAN A et al.: Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation (2002) 106(10):1205-1210.
   PubMed Web of Science ®Google Scholar
• SIMONS M, BONOW RO, CHRONOS NA et al.: Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation (2000) 102(11):E73-E86.
   PubMed Web of Science ®Google Scholar
• RUEL M, WU GF, KHAN TA et al.: Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation (2003) 108(Suppl. 1.):II335-II340.
   PubMed Web of Science ®Google Scholar
• VOISINE P, BIANCHI C, RUEL M et al.: Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery (2004) 136(2):407-415.
   PubMed Web of Science ®Google Scholar
• LAHAM R, SIMONS M: Growth factor therapy in ischemic heart disease. In: Angiogenesis in Health and Disease. Rubanyi G (Ed.) Marcel Decker, New York (2000):451-475.
   Google Scholar
• CARMELIET P: Mechanisms of angiogenesis and arteriogenesis. Nat. Med. (2000) 6(4):389-395.
   PubMed Web of Science ®Google Scholar
• YANCOPOULOS GD, DAVIS S, GALE NW et al.: Vascular-specific growth factors and blood vessel formation. Nature (2000) 407(6801):242-248.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, TAKAHASHI T, MASUDA H et al.: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO. J. (1999) 18(14):3964-3972.
   PubMed Web of Science ®Google Scholar
• TOFUKUJI M, METAIS C, LI J et al.: Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation (1998) 98(19 Suppl.):II242-II246; discussion II247-248.
   PubMed Web of Science ®Google Scholar
• LOPEZ JJ, LAHAM RJ, STAMLER A et al.: VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. (1998) 40(2):272-281.
   PubMed Web of Science ®Google Scholar
• HARADA K, FRIEDMAN M, LOPEZ JJ et al.: Vascular endothelial growth factor administration in chronic myocardial ischemia. Am. J. Physiol. (1996) 270(5 Pt 2):H1791-H1802.
   PubMed Web of Science ®Google Scholar
• RUTANEN J, RISSANEN TT, MARKKANEN JE et al.: Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation (2004) 109(8):1029-1035.
   PubMed Web of Science ®Google Scholar
• SCHALCH P, RAHMAN GF, PATEJUNAS G et al.: Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J. Thorac. Cardiovasc. Surg. (2004) 127(2):535-540.
   PubMed Web of Science ®Google Scholar
• TANAKA E, HATTAN N, ANDO K et al.: Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits. J. Thorac. Cardiovasc. Surg. (2000) 120(4):720-728.
   PubMed Web of Science ®Google Scholar
• BOODHWANI M, NAKAI Y, MIENO S et al.: Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann. Thorac. Surg. (In Press).
   Google Scholar
• LOPEZ JJ, LAHAM RJ, CARROZZA JP et al.: Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am. J. Physiol. (1997) 273(3 Pt 2):H1317-H1323.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1(1):27-31.
   PubMed Web of Science ®Google Scholar
• POST MJ, LAHAM R, SELLKE FW, SIMONS M: Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. (2001) 49(3):522-531.
   PubMed Web of Science ®Google Scholar
• SIMONS M, LAHAM R: Therapeutic angiogenesis in myocardial ischemia. In: Angiogenesis and cardiovascular disease. Ware J et al. (Eds) Oxford University press, New York (1999):289-320.
   Google Scholar
• LAHAM RJ, SELLKE FW, EDELMAN ER et al.: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a Phase I randomized, double-blind, placebo-controlled trial. Circulation (1999) 100(18):1865-1871.
   PubMed Web of Science ®Google Scholar
• LAHAM RJ, REZAEE M, POST M et al.: Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab. Dispos. (1999) 27(7):821-826.
   PubMed Web of Science ®Google Scholar
• LI J, POST M, VOLK R et al.: PR39, a peptide regulator of angiogenesis. Nat. Med. (2000) 6(1):49-55.
   PubMed Web of Science ®Google Scholar
• IYER NV, KOTCH LE, AGANI F et al.: Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. (1998) 12(2):149-162.
   PubMed Web of Science ®Google Scholar
• KASTRUP J, JORGENSEN E, RUCK A et al.: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. (2005) 45(7):982-988.
   PubMed Web of Science ®Google Scholar
• HEDMAN M, HARTIKAINEN J, SYVANNE M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 107(21):2677-2683.
   PubMed Web of Science ®Google Scholar
• FORTUIN FD, VALE P, LOSORDO DW et al.: One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am. J. Cardiol. (2003) 92(4):436-439.
   PubMed Web of Science ®Google Scholar
• MACCOLL GS, NOVO FJ, MARSHALL NJ et al.: Optimisation of growth hormone production by muscle cells using plasmid DNA. J. Endocrinol. (2000) 165(2):329-336.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA M, YAMAUCHI M, MORIMOTO K et al.: Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther. (2000) 7(7):548-555.
   PubMed Web of Science ®Google Scholar
• SHANGGUAN T, CABRAL-LILLY D, PURANDARE U et al.: A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine-condensed plasmid DNA. Gene Ther. (2000) 7(9):769-783.
   PubMed Web of Science ®Google Scholar
• ATIENZA C, JR., ELLIOTT MJ, DONG YB et al.: Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Int. J. Mol. Med. (2000) 6(1):55-63.
   PubMed Web of Science ®Google Scholar
• BILBAO R, GEROLAMI R, BRALET MP et al.: Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther. (2000) 7(5):657-662.
   PubMed Web of Science ®Google Scholar
• CHEN P, KOVESDI I, BRUDER JT: Effective repeat administration with adenovirus vectors to the muscle. Gene Ther. (2000) 7(7):587-595.
   PubMed Web of Science ®Google Scholar
• LEE EJ, THIMMAPAYA B, JAMESON JL: Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: implications for gene therapy. Neurosurgery (2000) 46(6):1461-1468; discussion 1468-1469.
   PubMed Web of Science ®Google Scholar
• HARTIGAN-O’CONNOR D, AMALFITANO A, CHAMBERLAIN JS: Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J. Virol. (1999) 73(9):7835-7841.
   PubMed Web of Science ®Google Scholar
• DRITTANTI L, RIVET C, MANCEAU P, DANOS O, VEGA M: High throughput production, screening and analysis of adeno-associated viral vectors. Gene Ther. (2000) 7(11):924-929.
   PubMed Web of Science ®Google Scholar
• HUDDE T, RAYNER SA, DE ALWIS M et al.: Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea (2000) 19(3):369-373.
   PubMed Web of Science ®Google Scholar
• SUN L, LI J, XIAO X: Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. (2000) 6(5):599-602.
   PubMed Web of Science ®Google Scholar
• DUAN D, YUE Y, YAN Z, ENGELHARDT JF: A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. (2000) 6(5):595-598.
   PubMed Web of Science ®Google Scholar
• NAKAI H, STORM TA, KAY MA: Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. (2000) 18(5):527-532.
   PubMed Web of Science ®Google Scholar
• RUDICH SM, ZHOU S, SRIVASTAVA R et al.: Dose response to a single intramuscular injection of recombinant adeno-associated virus-erythropoietin in monkeys. J. Surg. Res. (2000) 90(2):102-108.
   PubMed Web of Science ®Google Scholar
• HIRATA RK, RUSSELL DW: Design and packaging of adeno-associated virus gene targeting vectors. J. Virol. (2000) 74(10):4612-4620.
   PubMed Web of Science ®Google Scholar
• COSTELLO E, MUNOZ M, BUETTI E et al.: Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther. (2000) 7(7):596-604.
   PubMed Web of Science ®Google Scholar
• DUTHEIL N, SHI F, DUPRESSOIR T, LINDEN RM: Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc. Natl. Acad. Sci. USA (2000) 97(9):4862-4866.
   PubMed Web of Science ®Google Scholar
• PALU G, PAROLIN C, TAKEUCHI Y, PIZZATO M: Progress with retroviral gene vectors. Rev. Med. Virol. (2000) 10(3):185-202.
   PubMed Web of Science ®Google Scholar
• SOLAIMAN F, ZINK MA, XU G et al.: Modular retro-vectors for transgenic and therapeutic use. Mol. Reprod. Dev. (2000) 56(2 Suppl.):309-315.
   PubMed Web of Science ®Google Scholar
• MARSHALL E: Improving gene therapy’s tool kit. Science (2000) 288(5468):953.
   PubMedGoogle Scholar
• FOLLENZI A, AILLES LE, BAKOVIC S, GEUNA M, NALDINI L: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. (2000) 25(2):217-222.
   PubMed Web of Science ®Google Scholar
• JOHNSON LG, OLSEN JC, NALDINI L, BOUCHER RC: Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. (2000) 7(7):568-574.
   PubMed Web of Science ®Google Scholar
• CIOFFI L, STURTZ FG, WITTMER S et al.: A novel endothelial cell-based gene therapy platform for the in vivo delivery of apolipoprotein E. Gene Ther. (1999) 6(6):1153-1159.
   PubMed Web of Science ®Google Scholar
• POWELL C, SHANSKY J, DEL TATTO M et al.: Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum. Gene Ther. (1999) 10(4):565-577.
   PubMed Web of Science ®Google Scholar
• SU L, LEE R, BONYHADI M et al.: Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood (1997) 89(7):2283-2290.
   PubMed Web of Science ®Google Scholar
• ZHANG J, RUSSELL SJ: Vectors for cancer gene therapy. Cancer Metastasis Rev. (1996) 15(3):385-401.
   PubMed Web of Science ®Google Scholar
• WEI Y, QUERTERMOUS T, WAGNER TE: Directed endothelial differentiation of cultured embryonic yolk sac cells in vivo provides a novel cell-based system for gene therapy. Stem Cells (1995) 13(5):541-547.
   PubMed Web of Science ®Google Scholar
• TOMITA S, LI RK, WEISEL RD et al.: Autologous transplantation of bone marrow cells improves damaged heart function. Circulation (1999) 100(19 Suppl.):II247-II256.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, HAMANO K, LI TS et al.: Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. J. Surg. Res. (2000) 89(2):189-195.
   PubMed Web of Science ®Google Scholar
• GIORDANO FJ, PING P, MCKIRNAN MD et al.: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. (1996) 2(5):534-539.
   PubMed Web of Science ®Google Scholar
• IWATATE M, MIURA T, IKEDA Y et al.: Effects of in vivo gene transfer of fibroblast growth factor-2 on cardiac function and collateral vessel formation in the microembolized rabbit heart. Jpn. Circ. J. (2001) 65(3):226-231.
   PubMedGoogle Scholar
• MIAO W, LUO Z, KITSIS RN, WALSH K: Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J. Mol. Cell. Cardiol. (2000) 32(12):2397-2402.
   PubMed Web of Science ®Google Scholar
• LAI NC, ROTH DM, GAO MH et al.: Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation (2000) 102(19):2396-2401.
   PubMed Web of Science ®Google Scholar
• ROSENGART TK, LEE LY, PATEL SR et al.: Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation (1999) 100(5):468-474.
   PubMed Web of Science ®Google Scholar
• SYMES JF, LOSORDO DW, VALE PR et al.: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. (1999) 68(3):830-836; discussion 836-837.
   PubMed Web of Science ®Google Scholar
• FRENCH BA, MAZUR W, GESKE RS, BOLLI R: Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation (1994) 90(5):2414-2424.
   PubMed Web of Science ®Google Scholar
• MUHLHAUSER J, JONES M, YAMADA I et al.: Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther. (1996) 3(2):145-153.
   PubMed Web of Science ®Google Scholar
• HENDEL RC, HENRY TD, ROCHA-SINGH K et al.: Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation (2000) 101(2):118-121.
   PubMed Web of Science ®Google Scholar
• HENRY TD, ROCHA-SINGH K, ISNER JM et al.: Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am. Heart J. (2001) 142(5):872-880.
   PubMed Web of Science ®Google Scholar
• HENRY TD, ANNEX BH, MCKENDALL GR et al.: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 107(10):1359-1365.
   PubMed Web of Science ®Google Scholar
• FERGUSON JJ: Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation (1999) 100(6):570-575.
   PubMedGoogle Scholar
• RANA JS, MANNAM A, DONNELL-FINK L et al.: Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am. J. Cardiol. (2005) 95(12):1456-1459.
   PubMed Web of Science ®Google Scholar
• LOSORDO DW, VALE PR, SYMES JF et al.: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation (1998) 98(25):2800-2804.
   PubMed Web of Science ®Google Scholar
• ROSENGART TK, LEE LY, PATEL SR et al.: Six-month assessment of a Phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. (1999) 230(4):466-470; discussion 470-462.
   PubMed Web of Science ®Google Scholar
• VALE PR, LOSORDO DW, MILLIKEN CE et al.: Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation (2001) 103(17):2138-2143.
   PubMed Web of Science ®Google Scholar
• LOSORDO DW, VALE PR, HENDEL RC et al.: Phase I/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation (2002) 105(17):2012-2018.
   PubMed Web of Science ®Google Scholar
• VOISINE P, BIANCHI C, KHAN TA et al.: Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J. Thorac. Cardiovasc. Surg. (2005) 129(6):1414-1420.
   PubMed Web of Science ®Google Scholar
• DOR Y, DJONOV V, ABRAMOVITCH R et al.: Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO. J. (2002) 21(8):1939-1947.
   PubMed Web of Science ®Google Scholar
• ASAHARA T, BAUTERS C, ZHENG LP et al.: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation (1995) 92(9 Suppl.):II365-II371.
   PubMedGoogle Scholar